Category: pharma & healthcare

Sadly, the approval of a vaccine does not mark the beginning of the end of the pandemic—not if we don’t supplement it with public health measures. First on the list? Rapid testing.

High upfront costs make it hard for payers to underwrite the risk of full payment for one therapy, let alone the entire range of gene therapies in the pipeline. A combination of installment plans and value-based contracting will likely be the wave of t…

Borne from the pandemic, orthopaedic telemedicine finally arrives on the scene to offer patients direct access to the field’s leading experts.

In a recent study of cancer trends among adolescents and young adults in the US, researchers reported a stunning thirty percent increase in cancer diagnoses among individuals fifteen to thirty-nine years old between 1973 and 2015.

The Lancet Countdown report shows that extreme heat and infectious disease are taking their toll. It also says that Covid-19 will contextualize our response to climate change for many years to come.

Perhaps most worrying is the pervasive lack of transparency throughout the healthcare system, which compounds the asymmetry problem. Several key stakeholders benefit from the confusion. It’s in their financial interest to keep the system opaque.